CY
Insider
Catriona Yale
Chief Development OfficerCatriona Yale (Chief Development Officer) filed 12 Form 4 reports in the past 24 months (0 purchases, 12 sales, 4 filed past the two-business-day deadline), most often in AKRO. The largest single filing was $3.0M of AKRO (53,590 sh across 3 lots, as filed), executed Jan 27 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
12
0 buys · 12 sells · 4 late
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$8.6M
shares × price, as filed
Last traded
Jul 16 2025
Filed Jul 18 2025
Volume by month
Buys $0
Sells $8.6M
Shares × price, as filed · by filing month · past 24 months
Most traded names
AKRO
AKRO
0 buys · 12 sells
12 filings
Recent filings
AKROSALE
Akero Therapeutics, Inc.
View filing →
$3.0M53,590 sh across 3 lots
Exec Jan 27 2025
Filed Jan 31 2025 · 5:30 PM ET † AKROSALE Akero Therapeutics, Inc. View filing → $264K
9,074 sh × $29.11
Exec Dec 16 2024
Filed Dec 18 2024 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $243K
8,761 sh × $27.69
Exec Nov 15 2024
Filed Nov 19 2024 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $352K
10,000 sh × $35.19
Exec Nov 6 2024
Filed Nov 8 2024 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $652K
20,000 sh across 2 lots
Exec Oct 30 2024
Filed Nov 1 2024 · 5:30 PM ET